Prevalence of primary immune thrombocytopenia and related healthcare resource utilization among Texas Medicaid beneficiaries

References

• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113(26):6511–6521.
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–464.
   PubMed Web of Science ®Google Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24(10):2767–2776.
   PubMed Web of Science ®Google Scholar
• Palau J, Jarque I, Sanz MA. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med. 2010;3:305–311.
   PubMedGoogle Scholar
• Kim CY, Lee EH, Yoon HS. High remission rate of chronic immune thrombocytopenia in children: result of 20-year follow-up. Yonsei Med J. 2016;57(1):127–131.
   PubMed Web of Science ®Google Scholar
• Lozano ML, Mingot-Castellano ME, Perera MM, et al. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Blood Cells Mol Dis. 2021;86:102505.
   PubMed Web of Science ®Google Scholar
• Giordano P, Lassandro G, Barone A, et al. Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med. 2020;7:66.
   PubMed Web of Science ®Google Scholar
• Del Vecchio GC, De Santis A, Giordano P, et al. Management of acute childhood idiopathic thrombocytopenic purpura according to AIEOP consensus guidelines: assessment of Italian experience. Acta Haematol. 2008;119(1):1–7.
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–2383.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Neas BR, et al. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–852.
   PubMed Web of Science ®Google Scholar
• Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost. 2008;6(4):711–712.
   PubMed Web of Science ®Google Scholar
• An R, Wang PP. Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006–2012. Vasc Health Risk Manag. 2017;13:15–21.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hanau A, Hatfield M, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020;23(2):184–192.
   PubMed Web of Science ®Google Scholar
• Chapel JM, Ritchey MD, Zhang D, et al. Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries. Am J Prev Med. 2017;53(6S2):S143–S154.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health & Human Services. Who is eligible for Medicaid? [Internet]. Washington, DC; [cited 2020 Sep 7]. Available from: https://www.hhs.gov/answers/medicare-and-medicaid/who-is-eligible-for-medicaid/index.html.
   Google Scholar
• Plate JF, Ryan SP, Goltz DE, et al. Medicaid insurance correlates with increased resource utilization following total hip arthroplasty. J Arthroplasty. 2019;34(2):255–259.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):62–68.
   PubMed Web of Science ®Google Scholar
• Center for Medicaid and CHIP Services. Medicaid and CHIP beneficiary profile: characteristics, health status, access, utilization, expenditures, and experience. [Internet]. Baltimore, MD; [cited 2020 Sep 7]. Available from:https://www.medicaid.gov/medicaid/quality-of-care/downloads/beneficiary-profile.pdf.
   Google Scholar
• Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: what's the same, what's different? Haematologica. 2011;96(12):1739–1741.
   PubMed Web of Science ®Google Scholar
• Altomare I, Cetin K, Wetten S, et al. Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. Clin Epidemiol. 2016;20(8):231–239.
   Google Scholar
• Texas Health and Human Services Commission. Texas Medicaid and CHIP in perspective. 11th ed. [Internet]. Austin, TX. [cited 2020 Jan 5]. Available from: https://hhs.texas.gov/sites/default/files/documents/laws-regulations/reports-presentations/2017/medicaid-chip-perspective-11th-edition/11th-edition-complete.pdf.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Kruse A, Kruse C, Lambert MP. The ITP Natural History Study Registry: preliminary findings on the immune thrombocytopenia patient experience. Blood. 2018;132(Supplement 1):4979–4979.
   Web of Science ®Google Scholar
• Chong BH, Lee JW, Jang JH, et al. International ITP Registry with focus on the Asia Pacific Region: update on preliminary findings of epidemiological and clinical data. Blood. 2017;130(Supplement 1):4853.
   Google Scholar
• Pontikoglou C, Stavroulaki E, Tzikoulis V, et al. Demographic, clinical and laboratory features, management and outcome of immune thrombocytopenia (ITP) in Greece: The National ITP Registry of the Hellenic Society of Hematology. Blood. 2017;130(Supplement 1):4859.
   Google Scholar
• Strand V, Tundia N, Song Y, et al. Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis. JMCP. 2018;24(4):344–352.
   PubMed Web of Science ®Google Scholar
• Sussman M, O'Sullivan AK, Shah A, et al. Economic burden of treatment-resistant depression on the U.S. health care system. J Manag Care Spec Pharm. 2019;25(7):823–835.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Spec Pharm. 2008;14(2):164–175.
   PubMed Web of Science ®Google Scholar